MedTrace Logo

Tamoxifen in Treating Patients With Primary Liver Cancer

NCT00003424 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2013-06-26

No results posted yet for this study

Summary

RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using tamoxifen may fight liver cancer by blocking the absorption of estrogen. It is not yet known whether receiving tamoxifen is more effective than no further therapy in treating patients with primary liver cancer.

PURPOSE: Randomized phase III trial to compare high-dose tamoxifen with no further treatment in treating patients with liver cancer that cannot be surgically removed.

Conditions

Interventions

DRUG

tamoxifen citrate

Sponsors & Collaborators

  • National Medical Research Council (NMRC), Singapore

    lead OTHER_GOV

Principal Investigators

  • Pierce Chow, MD, PhD, MBBS, FRCS, FAMS · National Cancer Centre, Singapore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
10 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-04-30
Primary Completion
2000-06-30
Completion
2009-08-31

Countries

  • Hong Kong
  • Indonesia
  • Malaysia
  • New Zealand
  • Pakistan
  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003424 on ClinicalTrials.gov